Fungi-Nail Lawsuit Claims Antifungal Brand Misled Shoppers About Nail Fungus Treatment

Case Overview: A class action says Fungi-Nail falsely promoted its antifungal liquid as a nail fungus cure despite disclaimers stating otherwise.

Consumers Affected: Buyers who purchased Fungi-Nail believing it could treat nail fungus.

Court: U.S. District Court for the Eastern District of North Carolina

Shoppers who reached for Fungi-Nail believing it would cure nail fungus may have been misled, according to a new lawsuit accusing Arcadia Consumer Healthcare of deceptive marketing.

Filed in North Carolina federal court, the case claims the company sold an antifungal liquid that never performed the way its packaging suggested. 

Plaintiff Daniel Duffey purchased the treatment expecting it to address nail fungus after reading front-label phrases such as “clinically proven to cure and prevent fungal infections” and “triple action formula.”

Only later, he says, did he notice a disclaimer printed in small type on the back of the box stating that the product is not meant for nail infections at all.

Plaintiff Says Branding and Packaging Misled Buyers

Everything about the product’s presentation, Duffey contends, points buyers toward the wrong conclusion. The name Fungi-Nail, the images of smooth nails, and the bold claims about killing fungus all reinforce the impression that the medicine penetrates the nail. 

In practice, the suit says, the formula’s active ingredient treats only the surrounding skin and cannot reach the infection beneath the nail plate.

That gap between message and capability, the lawsuit alleges, misleads consumers into spending money on something that can’t do what they bought it for. In the text of the complaint, 

Duffey’s lawsuit contends that the back-label disclaimer “directly contradicts the overall marketing message appearing on the front of the packaging.”

Company Allegedly Profited From False Marketing Claims

Court documents describe a pattern of advertising that generated “millions of dollars in fraudulent sales.” Duffey maintains that Arcadia presented a basic topical antifungal as a nail cure, driving sales among people eager for an at-home remedy. 

He says consumers paid premium prices for a treatment that lacked the ability to reach or eliminate nail infections.

The filing also draws attention to everyday purchasing behavior. Most buyers, it says, rely on front-label claims when selecting personal care products and rarely examine the detailed ingredient lists.

By placing the limitation in fine print, Arcadia allegedly created an unfair advantage in the marketplace.

Case Adds to Growing Scrutiny Over OTC Health Product Advertising

The case joins a growing wave of lawsuits challenging how over-the-counter products are marketed to consumers. In July, plaintiffs sued over Orajel Baby Teething Swabs and Zicam Nasal Swabs, alleging that the products contained fungal contaminants despite being labeled safe for use.

In the Fungi-Nail lawsuit, Duffey is asking for refunds and compensation for purchasers nationwide, along with a subclass for North Carolina buyers. The filing includes claims of fraud, negligent misrepresentation, breach of warranty, and unjust enrichment. 

Along with financial restitution, he wants an injunction that would bar Arcadia from marketing Fungi-Nail as a nail fungus treatment unless its label and advertising are changed.

Case Details

• Lawsuit: Duffey v. Arcadia Consumer Healthcare Inc.
• Case Number: 5:25-cv-00652
• Court: U.S. District Court for the Eastern District of North Carolina

Plaintiffs' Attorney:

• Daquan Blyther (Solomon Law Group PLLC)
• Thiago M. Coelho (Wilshire Law Firm PLC)

Have you ever tried Fungi-Nail or other over-the-counter antifungal treatments? Share your experience or thoughts about this lawsuit in the comments below.